| Literature DB >> 32555690 |
Pei-Lun Chu1,2, Hui-Shan Liu3, Chikang Wang4, Chien-Yu Lin1,4,5.
Abstract
INTRODUCTION: Acrylamide is widely present in heat-processed food, cigarette smoke and environment. Reproductive toxicity was reported in animals treated with acrylamide, particularly in males. The reproductive toxicity of acrylamide and its active metabolite, glycidamide, was reported to be mainly mediated through DNA damage in spermatocytes. However, the effect of acrylamide on sex hormones in men is unknown.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32555690 PMCID: PMC7302712 DOI: 10.1371/journal.pone.0234622
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Basic demographics of the sample subjects including means (95% C.I.) of acrylamide and glycidamide adduct concentrations.
| Unweighted no. (%) | HbAA (pmol/g Hb) | Unweighted no. (%) | HbGA (pmol/g Hb) | |||
|---|---|---|---|---|---|---|
| Overall | 468 (100) | 78.91 (72.82–85.01) | 454 (100) | 69.71 (64.42–75.00) | ||
| Age, y | <0.001 | <0.001 | ||||
| 12–19 | 161 (34.4) | 69.26 (59.17–79.35) | 156 (34.4) | 64.10 (55.29–72.91) | ||
| 20–44 | 133 (28.4) | 100.69 (85.49–115.88) | 130 (28.6) | 86.48 (74.33–98.64) | ||
| ≧45 | 174 (37.2) | 71.20 (62.67–79.73) | 168 (37.0) | 61.95 (54.14–69.75) | ||
| Race | 0.204 | 0.274 | ||||
| Mexican American | 122 (26.1) | 77.56 (65.65–89.47) | 117 (25.8) | 74.35 (63.93–84.76) | ||
| Non-Hispanic White | 201 (42.9) | 77.95 (68.66–87.22) | 198 (43.6) | 70.03 (62.03–78.04) | ||
| Non-Hispanic Black | 113 (24.2) | 87.88 (75.50–100.26) | 108 (23.8) | 68.49 (57.64–79.33) | ||
| Others Hispanic | 16 (3.4) | 47.44 (14.54–80.35) | 16 (3.5) | 39.94 (11.81–68.08) | ||
| Other race | 16 (3.4) | 69.62 (36.72–102.52) | 15(3.3) | 69.90 (40.84–98.96) | ||
| BMI z score | <0.001 | 0.024 | ||||
| ≦ 0.15 | 232 (50.1) | 92.85 (84.33–101.37) | 226 (50.3) | 75.90 (64.41–83.40) | ||
| >0.15 | 231 (49.9) | 65.34 (56.80–73.88) | 223 (49.7) | 63.67 (56.12–71.21) | ||
| Smoking | < 0.001 | < 0.001 | ||||
| Nonexposed | 64 (13.7) | 50.28 (36.40–64.16) | 60 (13.2) | 52.37 (39.26–65.49) | ||
| Exposed to ETS | 264 (56.4) | 56.39 (49.56–63.23) | 257 (56.6) | 53.49 (47.16–59.83) | ||
| Active smoker | 140 (29.9) | 134.47 (125.09–143.86) | 137 (30.2) | 107.73 (99.05–116.41) | ||
| Caffeine intake (mg/day) | 0.006 | 0.004 | ||||
| < 72 | 205 (49.6) | 68.27 (59.41–77.13) | 199 (49.6) | 61.08 (53.32–68.85) | ||
| ≧72 | 208 (50.3) | 85.96 (77.04–94.89) | 202 (50.4) | 77.00 (69.30–84.71) |
Linear regression coefficients (S.E.) of sex hormones with a unit increase in ln-acrylamide and glycidamide adduct concentrations, with results weighted for sampling strategy.
| Unweighted no./ Population size | Ln HbAA (pmol/g Hb) | Unweighted no./ Population size | Ln HbGA (pmol/g Hb) | |||
|---|---|---|---|---|---|---|
| Ln AMH (ng/ml) | ||||||
| Unadjusted | 460/14985390 | 0.31(0.12) | 0.017 | 447/14627589 | 0.32(0.09) | 0.003 |
| Adjusted | 455/14798997 | 0.24(0.14) | 0.118 | 442/14451196 | 0.31(0.09) | 0.003 |
| Ln Inhibin B (pg/ml) | ||||||
| Unadjusted | 452/14740305 | 0.14(0.05) | 0.011 | 439/14392504 | 0.07(0.03) | 0.041 |
| Adjusted | 447/14563912 | 0.10(0.05) | 0.046 | 434/14216111 | 0.04(0.03) | 0.104 |
| Ln SHBG(nmol/L) | ||||||
| Unadjusted | 465/15088650 | 0.18(0.06) | 0.007 | 451/14729272 | -0.01(0.04) | 0.855 |
| Adjusted | 460/14912257 | 0.15(0.07) | 0.036 | 446/14552879 | -0.05(0.04) | 0.230 |
| Ln total Testosterone (ng/mL) | ||||||
| Unadjusted | 465/15088650 | 0.24(0.06) | 0.001 | 451/14729272 | 0.06(0.04) | 0.134 |
| Adjusted | 460/14912257 | 0.11(0.06) | 0.099 | 446/14552879 | -0.01(0.04) | 0.794 |
| Ln free Testosterone (ng/mL) | ||||||
| Unadjusted | 465/15088650 | 0.13(0.07) | 0.095 | 451/14729272 | 0.07(0.05) | 0.179 |
| Adjusted | 460/14912257 | 0.00(0.08) | 0.996 | 446/14552879 | 0.02(0.05) | 0.782 |
| Ln bioavailable Testosterone (ng/mL) | ||||||
| Unadjusted | 465/15088650 | 0.19(0.08) | 0.028 | 451/14729272 | 0.11(0.059) | 0.094 |
| Adjusted | 460/14912257 | 0.09(0.11) | 0.441 | 446/14552879 | 0.06(0.075) | 0.438 |
| Ln Estradiol (pg/mL) | ||||||
| Unadjusted | 453/14994792 | 0.08(0.05) | 0.097 | 439/14635413 | 0.02(0.04) | 0.623 |
| Adjusted | 449/14824285 | 0.03(0.07) | 0.703 | 435/14464906 | -0.02(0.04) | 0.659 |
| Ln Androstanedione glucuronide (ng/mL) | ||||||
| Unadjusted | 464/15023095 | -0.07(0.08) | 0.398 | 468/14663717 | -0.00(0.05) | 0.951 |
| Adjusted | 459/14846702 | -0.03(0.08) | 0.665 | 445/14487324 | 0.03(0.03) | 0.405 |
a, Model adjusted for age, race/ethnicity, BMI z score and smoking status
Abbreviations: AMH: anti-Mullerian hormone; SHBG: sex hormone binding globulin
Linear regression coefficients (SE) between ln-HbAA, inhibin B, and SHBG in different subpopulations of sample subjects with results weighted for sampling strategy.
| Unweighted no./ Population size | Ln inhibin B (ng/ml) | Unweighted no./ Population size | Ln SHBG (ng/ml) | |||
|---|---|---|---|---|---|---|
| β coeff (S.E.) | P value | β coeff (S.E.) | P value | |||
| Age, y | ||||||
| 12–19 | 156/2088544 | 0.07 (0.01) | 0.496 | 159/2145120 | 0.21 (0.12) | 0.118 |
| 20–44 | 130/6679231 | 0.38 (0.12) | 0.321 | 130/6735835 | 0.09 (0.09) | 0.350 |
| ≧45 | 161/5796137 | 0.13 (0.07) | 0.068 | 171/5796137 | 0.23 (0.11) | 0.047 |
| Race | ||||||
| Non-Hispanic White | 191/10201001 | 0.14 (0.05) | 0.026 | 198/10490006 | 0.17 (0.07) | 0.035 |
| Others | 256/4362911 | 0.02 (0.07) | 0.757 | 262/4422251 | 0.09 (0.07) | 0.215 |
| Serum cotinine (ng/mL) | ||||||
| <0.142 | 221/6473948 | 0.24 (0.08) | 0.008 | 229/6650284 | 0.15 (0.13) | 0.242 |
| ≧0.142 | 226/8089964 | 0.05 (0.07) | 0.460 | 231/8261973 | 0.15 (0.06) | 0.018 |
| BMI z score | ||||||
| ≦ 0.15 | 225/8028661 | 0.08 (0.07) | 0.267 | 230/8105091 | 0.08 (0.07) | 0.270 |
| >0.15 | 222/6535250 | 0.15 (0.09) | 0.121 | 230/6807166 | 0.27 (0.07) | 0.001 |
Model adjusted for age, race/ethnicity, BMI z score and smoking status
Abbreviations: BMI z score, z score of body mass index.
Linear regression coefficients (SE) between ln-HbGA and AMH in different subpopulations of sample subjects with results weighted for sampling strategy.
| Unweighted no./ Population size | Ln anti-Mullerian hormone (ng/ml) | ||
|---|---|---|---|
| β coeff (S.E.) | P value | ||
| Age, y | |||
| 12–19 | 152/2033039 | 0.17 (0.08) | 0.054 |
| 20–44 | 128/6696375 | 0.38 (0.12) | 0.007 |
| ≧45 | 162/5721783 | 0.22 (0.13) | 0.095 |
| Race | |||
| Non-Hispanic White | 194/10248799 | 0.31 (0.10) | 0.010 |
| Others | 248/4202397 | 0.31 (0.16) | 0.066 |
| Serum cotinine (ng/mL) | |||
| <0.142 | 221/6469051 | 0.32 (0.20) | 0.128 |
| ≧0.142 | 221/7982145 | 0.29 (0.10) | 0.012 |
| BMI z score | |||
| ≦ 0.15 | 225/7994319 | 0.23 (0.10) | 0.040 |
| >0.15 | 217/6456877 | 0.46 (0.18) | 0.020 |
Model adjusted for age, race/ethnicity, BMI z score and smoking status
Abbreviations: AMH, anti-Mullerian hormone; BMI z score, z score of body mass index.